A recently published meta-analysis of pooled data from 11 randomized controlled trials of GLP-1 receptor agonists in patients with NAFLD or NASH indicated significant improvements in liver enzyme levels and liver fat content following treatment (70). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.